<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206049</url>
  </required_header>
  <id_info>
    <org_study_id>2010-020385-13</org_study_id>
    <nct_id>NCT01206049</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations</brief_title>
  <acronym>GOC-B-P</acronym>
  <official_title>Randomized Phase II Trial of Combination Chemotherapy With Panitumumab or Bevacizumab for Patients With Inoperable Cholangiocarcinoma Without KRAS Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the rate of progression free survival of patients
      with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are
      treated with combination chemotherapy supplemented by biological agents panitumumab or
      bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The fraction of patients alive and without progression at 6 months</measure>
    <time_frame>6 months from enrollment date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate before cross-over</measure>
    <time_frame>6 months after enrollment or earlier in case of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and response rate after cross-over</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Combination chemotherapy + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination chemotherapy + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1,000 mg/m2 on day 1 of a 2 weeks cycle</description>
    <arm_group_label>Combination chemotherapy + panitumumab</arm_group_label>
    <arm_group_label>Combination chemotherapy + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>60 mg/m2 on day 1 of a 2 weeks cycle</description>
    <arm_group_label>Combination chemotherapy + panitumumab</arm_group_label>
    <arm_group_label>Combination chemotherapy + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle</description>
    <arm_group_label>Combination chemotherapy + panitumumab</arm_group_label>
    <arm_group_label>Combination chemotherapy + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>6 mg/kg on day 1 of a 2 weeks cycle</description>
    <arm_group_label>Combination chemotherapy + panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg on day 1 of a 2 weeks cycle</description>
    <arm_group_label>Combination chemotherapy + bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified adenocarcinoma arisen from gall bladder, extra- or
             intrahepatic bile ducts or malignant cells consistent with the above and simultaneous
             radiologic findings consistent with cholangiocarcinoma

          -  Minimum 18 years of age

          -  Curative treatment currently not an option (operation, stereotactic radiation
             treatment or similar)

          -  KRAS analyzed and found wild-type (wt)

          -  Performance status 0-2

          -  Evaluable disease according to RECIST, i.e. the disease need not be measurable

          -  Hematology: ANC ≥1.5x10^9/l. Thrombocytes ≥ 100x10^9/l

          -  Biochemistry: Bilirubinemia ≤ 3 x upper normal level. ALAT ≤ 5 x upper normal level.

          -  Creatinine ≤ upper normal level. At raised creatinine level the measured or calculated
             GFR must be at least 50% of the lower normal level

          -  Fertile women must present a negative pregnancy test and use secure birth control
             during and 6 months after treatment. Men with fertile partners must also take care of
             secure birth control.

          -  Written and orally informed consent

        Exclusion Criteria:

          -  Previous cytostatic treatment of inoperable cholangiocarcinoma

          -  Adjuvant or neoadjuvant chemotherapy, radiation therapy or immunotherapy within 4
             weeks prior to treatment start

          -  Other concomitant experimental treatment

          -  Severe medical disease such as considerable heart disease, serious active infection or
             other disease making the patient unfit for study participation as assessed by
             investigator

          -  Other malignant disease within 5 years prior to enrolment except from non-melanotic
             skin cancer and carcinoma in situ cervicis uteri

          -  Interstitial pneumonitis or subsequent pulmonary fibrosis

          -  Pregnant or breastfeeding women

          -  Large-scale surgical intervention, excision biopsy or significant traumatic lesions
             within 28 days prior to treatment start or presumption that large-scale surgery will
             become necessary during study treatment.

          -  Significant non-healing wound or ulcers

          -  Active hemorrhage or increased risk of hemorrhage (e.g. tumor invasion in large
             vessels or known esophagus varices)

          -  Known hypersensitivity to panitumumab, bevacizumab or any of the auxiliary agents

          -  Grade IV fistulas

          -  Uncontrolled hypertension, i.e. symptomatic hypertension or non-medically stabilized
             hypertension &gt;160/100

          -  Haemoptysis &gt; 2.5 ml within 2 weeks prior to enrolment

          -  Previous serious and unexpected reactions or know hypersensitivity to two or more of
             the applied cytostatics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Inoperable</keyword>
  <keyword>KRAS mutation</keyword>
  <keyword>Biological treatment</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

